The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Current Status of Gendicine in China: Recombinant Human Ad-p53 Agent for Treatment of Cancers
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Activation of Bax by p53 Mediates Mitochondrial Membrane Permeabilization and Apoptosis
Chipuk, J. E., Kuwana, T., Bouchier-Hayes, L., Droin, N. M., Newmeyer, D. D., Schuler, M., & Green, D. R. (2004) · Science · doi:10.1126/science.1092734 · Cited by 2,108
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,438
Multidrug resistance (MDR) in cancer
Krishna, R., & Mayer, L. D. (2000) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(00)00114-7 · Cited by 1,026
p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs
Müller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M., Friedman, S. L., Galle, P. R., Stremmel, W., Oren, M., et al. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2033 · Cited by 878
Mitochondrial p53 activates Bak and causes disruption of a Bak–Mcl1 complex
Leu, J. I.-J., Dumont, P., Hafey, M., Murphy, M. E., & George, D. L. (2004) · Nature Cell Biology · doi:10.1038/ncb1123 · Cited by 770
Cell Surface Trafficking of Fas: A Rapid Mechanism of p53-Mediated Apoptosis
Bennett, M., Macdonald, K., Chan, S.-W., Luzio, J. P., Simari, R., & Weissberg, P. (1998) · Science · doi:10.1126/science.282.5387.290 · Cited by 754
The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression
Schwartzenberg-Bar-Yoseph, F., Armoni, M., & Karnieli, E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-0846 · Cited by 726
Lang, F. F., Bruner, J. M., Fuller, G. N., Aldape, K., Prados, M. D., Chang, S., Berger, M. S., McDermott, M. W., Kunwar, S. M., Junck, L. R., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.21.13.2508 · Cited by 395
Clayman, G. L., el-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2221 · Cited by 371
Biopharmaceutical benchmarks 2006
Walsh, G. (2006) · Nature Biotechnology · doi:10.1038/nbt0706-769 · Cited by 359
Nemunaitis, J., Swisher, S. G., Timmons, T., Connors, D., Mack, M., Doerksen, L., Weill, D., Wait, J., Lawrence, D. D., Kemp, B. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.609 · Cited by 322
China approves first gene therapy
Pearson, S., Jia, H., & Kandachi, K. (2004) · Nature Biotechnology · doi:10.1038/nbt0104-3 · Cited by 255
p53 and Nur77/TR3 – transcription factors that directly target mitochondria for cell death induction
Moll, U. M., Marchenko, N., & Zhang, X.-K. (2006) · Oncogene · doi:10.1038/sj.onc.1209601 · Cited by 240
Adenoviral vectors for gene therapy
Douglas, J. T. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0021-5 · Cited by 236
Regulatory Approvals of Pediatric Oncology Drugs: Previous Experience and New Initiatives
Hirschfeld, S., Ho, P. T. C., Smith, M., & Pazdur, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.138 · Cited by 229
Bouvard, V., Zaitchouk, T., Vacher, M., Duthu, A., Canivet, M., Choisy-Rossi, C., Nieruchalski, M., & May, E. (2000) · Oncogene · doi:10.1038/sj.onc.1203366 · Cited by 220
p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas
Singh, B., Reddy, P. G., Goberdhan, A., Walsh, C., Dao, S., Ngai, I., Chou, T. C., O-charoenrat, P., Levine, A. J., Rao, P. H., et al. (2002) · Genes & Development · doi:10.1101/gad.973602 · Cited by 218
Schuler, M., Herrmann, R., De Greve, J. L. P., Stewart, A. K., Gatzemeier, U., Stewart, D. J., Laufman, L., Gralla, R., Kuball, J., Buhl, R., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1750 · Cited by 210
Pal, S., Datta, K., & Mukhopadhyay, D. (2001) · PubMed · Cited by 196
NKG2D ligands: unconventional MHC class I‐like molecules exploited by viruses and cancer
Cerwenka, A., & Lanier, L. L. (2003) · Tissue Antigens · doi:10.1034/j.1399-0039.2003.00070.x · Cited by 167
Essential Role for Caspase-8 in Transcription-independent Apoptosis Triggered by p53
Ding, H., Lin, Y., McGill, G. G., Juo, P., Zhu, H., Blenis, J., Yuan, J., & Fisher, D. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004714200 · Cited by 146
PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression
Yin, Y., Liu, Y., Jin, Y. J., Hall, E. J., & Barrett, J. C. (2003) · Nature · doi:10.1038/nature01519 · Cited by 145
Kuball, J. H. E., Wen, S. F., Leissner, J., Atkins, D., Meinhardt, P., Quijano, E., Engler, H., Hutchins, B., Maneval, D. C., Grace, M. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.4.957 · Cited by 135
Down-regulation of Sphingosine Kinase-1 by DNA Damage
Taha, T. A., Osta, W. A., Kozhaya, L., Bielawski, J., Johnson, K. R., Gillanders, W. E., Dbaibo, G. S., Hannun, Y. A., & Obeid, L. M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401259200 · Cited by 131
p53AIP1 regulates the mitochondrial apoptotic pathway.
Matsuda, K., Yoshida, K., Taya, Y., Nakamura, K., Nakamura, Y., & Arakawa, H. (2002) · PubMed · Cited by 120
Jung, C., Yoo, J., Jang, Y. J., Kim, S. S., Chu, I., Yeom, Y. I., Choi, J. Y., & Im, D. (2006) · Hepatology · doi:10.1002/hep.21137 · Cited by 116
Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S.-Y., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 96
CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance
Rosenblum, M. D., Olasz, E. B., Woodliff, J. E., Johnson, B. D., Konkol, M. C., Gerber, K. A., Orentas, R. J., Sandford, G. R., & Truitt, R. L. (2003) · Blood · doi:10.1182/blood-2003-09-3184 · Cited by 82
DNA damage, p14ARF, Nucleophosmin (NPM/B23), and cancer
Gjerset, R. A. (2006) · Journal of Molecular Histology · doi:10.1007/s10735-006-9040-y · Cited by 75
Ala‐aho, R., Grenman, R. A., Seth, P. K., & Kähäri, V. (2002) · Oncogene · doi:10.1038/sj.onc.1205198 · Cited by 70
Identification of Tcf-4 as a transcriptional target of p53 signalling
Rother, K., Johne, C., Spiesbach, K., Haugwitz, U., Tschöp, K., Wasner, M., Klein‐Hitpaß, L., Möröy, T., Mössner, J., & Engeland, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207464 · Cited by 66
Yen, N., Ioannides, C. G., Xu, K., Swisher, S. G., Lawrence, D. D., Kemp, B. L., El‐Naggar, A. K., Cristiano, R. J., Fang, B., Glisson, B. S., et al. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700138 · Cited by 65
Brasseur, G., Infossi, P., Dujardin, G., Słonimski, P. P., & Brivet‐Chevillotte, P. (1997) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1997.t01-1-00103.x · Cited by 60
Sun, Y., Zeng, X., Wenger, L., Firestein, G. S., & Cheung, H. S. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20044 · Cited by 57
Iiizumi, M., Arakawa, H., Mori, T., Ando, A., & Nakamura, Y. (2002) · PubMed · Cited by 49
Importance of p53 for cancer onset and therapy
Haupt, S., & Haupt, Y. (2006) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000217422.52208.fa · Cited by 44
Gene therapy of liver diseases
Prìeto, J., Qian, C., Hernández-Alcoceba, R., González‐Aseguinolaza, G., Mazzolini, G. D., Sangro, B., & Kramer, M. G. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1073 · Cited by 43
Särkioja, M., Kanerva, A., Salo, J., Kangasniemi, L., Eriksson, M. R., Raki, M., Ranki, T., Hakkarainen, T., & Hemminki, A. (2006) · Cancer · doi:10.1002/cncr.22209 · Cited by 40
Gene Therapy for Lung Neoplasms
Vachani, A., Moon, E. K., Wakeam, E., Haas, A. R., Sterman, D. H., & Albelda, S. Μ. (2011) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2011.08.006 · Cited by 38
Sah, N. K., Munshi, A., Nishikawa, T., Mukhopadhyay, T., Roth, J. A., & Meyn, R. E. (2003) · PubMed · Cited by 35
Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
Palacios, G. F., & Moll, U. M. (2006) · Oncogene · doi:10.1038/sj.onc.1209641 · Cited by 32
Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
Ternovoi, V. V., Curiel, D. T., Smith, B. F., & Siegal, G. P. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700444 · Cited by 31
Hu, X., Ma, Q., & Zhang, S. (2006) · Biotechnology Journal · doi:10.1002/biot.200600083 · Cited by 31
Can China bring its own pipeline to the market?
Louët, S. (2004) · Nature Biotechnology · doi:10.1038/nbt1204-1497 · Cited by 25
Cationic lipids for gene deliveryin vitroandin vivo
Rao, N. M., & Gopal, V. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.6.825 · Cited by 23
Contributions of E1A to mouse adenovirus type 1 pathogenesis following intranasal inoculation
Weinberg, J. B., Jensen, D. R., Gralinski, L. E., Lake, A. R., Stempfle, G. S., & Spindler, K. R. (2006) · Virology · doi:10.1016/j.virol.2006.08.013 · Cited by 21
Callahan, S. M., Boquet, M. P., Ming, X., Brunner, L. J., & Croyle, M. A. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.884 · Cited by 20
Step into the Groove: Engineered Transcription Factors as Modulators of Gene Expression
Visser, A. E., Verschure, P. J., Gommans, W. M., Haisma, H. J., & Rots, M. G. (2006) · Advances in genetics · doi:10.1016/s0065-2660(06)56004-3 · Cited by 16
Yang, C. H., & Cristofanilli, M. (2006) · Future Oncology · doi:10.2217/14796694.2.2.247 · Cited by 11
Figueiredo, M. L., Sato, M., Johnson, M., & Wu, L. (2006) · Future Oncology · doi:10.2217/14796694.2.3.391 · Cited by 10
M ulti d rug r esistance (MDR)
Wada, M., Hasegawa, S., Kohno, K., et al. (2015) · The Dictionary of Genomics, Transcriptomics and Proteomics · doi:10.1002/9783527678679.dg08011 · Cited by 9
Cited by
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Gene therapy clinical trials worldwide to 2012 – an update
Ginn, S. L., Alexander, I. E., Edelstein, M. L., Abedi, M. R., & Wixon, J. (2013) · The Journal of Gene Medicine · doi:10.1002/jgm.2698 · Cited by 1,159
Assessment of the Evolution of Cancer Treatment Therapies
Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., Lambea, J., Tres, A., Valladares, M., & González-Fernández, Á. (2011) · Cancers · doi:10.3390/cancers3033279 · Cited by 931
Lee, C. S., Bishop, E. S., Zhang, R., Yu, X., Farina, E. M., Yan, S., Zhao, C., Zeng, Z., Shu, Y., Wu, X., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2017.04.001 · Cited by 691
Metadata
- Authors
- Peng, Z.
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2005-09
- Volume
- 16
- Issue
- 9
- Pages
- 1016-1027
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2014780970
- Cited by
- 436
- References
- 51
- FWCI
- 16.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.